This recommendation specifically applies to finerenone and is graded as Level A. The guidelines for patients with eGFRs ≥ 20 mL/min/1.73 m2 propose using an SGLT2 inhibitor, a GLP-1 receptor agonist, or an nsMRA (if the eGFR is ≥ 25 mL/min/1.73 m2) to reduce cardiovascular risk in patients with T2D and CKD. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.